Filing Details

Accession Number:
0001415889-24-009249
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-27 18:54:49
Reporting Period:
2024-03-25
Accepted Time:
2024-03-27 18:54:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808158 Repare Therapeutics Inc. RPTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1477123 Mitchell Lloyd Segal C/O Repare Therapeutics Inc.
St-Laurent A8 H4S 1Z9
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2024-03-25 2,650 $4.79 89,166 No 4 S Indirect See footnote
Common Shares Disposition 2024-03-26 2,650 $4.64 86,516 No 4 S Indirect See footnote
Common Shares Disposition 2024-03-27 2,650 $4.63 83,866 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares 124,677 Direct
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5).
  3. These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.83 inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.77 inclusive.